Recce Pharmaceuticals (R9Q) Stock Overview

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. More details

R9Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 55.33% per year

Risk Analysis

Negative shareholders equity

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (A$975K)

Highly volatile share price over the past 3 months compared to the German market

+ 1 more risk

R9Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Recce Pharmaceuticals Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Recce Pharmaceuticals
Historical stock prices
Current Share Price	AU$0.27
52 Week High	AU$0.45
52 Week Low	AU$0.13
Beta	0.39
1 Month Change	5.43%
3 Month Change	1.49%
1 Year Change	74.36%
3 Year Change	-29.17%
5 Year Change	-54.29%
Change since IPO	-16.02%

Recent updates

Shareholder Returns

	R9Q	DE Pharmaceuticals	DE Market
7D	-2.9%	3.9%	-0.9%
1Y	74.4%	29.3%	1.9%

Return vs Industry: R9Q exceeded the German Pharmaceuticals industry which returned 23.1% over the past year.

Return vs Market: R9Q exceeded the German Market which returned 3.3% over the past year.

Price Volatility

Is R9Q's price volatile compared to industry and market?
R9Q volatility
R9Q Average Weekly Movement	14.3%
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	5.8%
10% most volatile stocks in DE Market	13.4%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: R9Q's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: R9Q's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2007	n/a	James Graham	www.recce.com.au

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections.

Recce Pharmaceuticals Ltd Fundamentals Summary

How do Recce Pharmaceuticals's earnings and revenue compare to its market cap?
R9Q fundamental statistics
Market cap	€89.91m
Earnings (TTM)	-€18.44m
Revenue (TTM)	€594.10k

151.3x

P/S Ratio

-4.9x

P/E Ratio

Is R9Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
R9Q income statement (TTM)
Revenue	AU$974.56k
Cost of Revenue	AU$12.15m
Gross Profit	-AU$11.18m
Other Expenses	AU$19.07m
Earnings	-AU$30.25m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.10
Gross Margin	-1,147.19%
Net Profit Margin	-3,104.24%
Debt/Equity Ratio	0%

How did R9Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/17 14:39
End of Day Share Price	2026/06/17 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jyoti Prakash	Edison Investment Research
Chris Kallos	MST Financial Services Pty Limited

Recce Pharmaceuticals (R9Q) Stock Overview

Rewards

Risk Analysis

Recce Pharmaceuticals Ltd Competitors

MPH Health Care

Cantourage Group

Biofrontera

PEPTONIC medical

Price History & Performance

Recent News & Updates

Less than half of directors are independent

Recce Pharmaceuticals Ltd Receives AUD 5.3 Million R&D Rebate

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 05, 2025

Recce Pharmaceuticals Ltd announced that it expects to receive AUD 30 million in funding from Avenue Capital Management II, L.P.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 10.828449 million.

Recce Pharmaceuticals Ltd Announces Cash Receipt from Canadian Government as Part of Its Scientific Research & Experimental Development (SR&ED) Tax Incentive Program

Recent updates

Less than half of directors are independent

Recce Pharmaceuticals Ltd Receives AUD 5.3 Million R&D Rebate

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 05, 2025

Recce Pharmaceuticals Ltd announced that it expects to receive AUD 30 million in funding from Avenue Capital Management II, L.P.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 10.828449 million.

Recce Pharmaceuticals Ltd Announces Cash Receipt from Canadian Government as Part of Its Scientific Research & Experimental Development (SR&ED) Tax Incentive Program

Recce Pharmaceuticals Receives Approval for Additional Phase Ii Trial of Recce® 327 Topical Gel for Diabetic Foot Infections

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 5 million.

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Recce Pharmaceuticals Grants Japanese Patent for RECCE Anti-Infectives

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of Recce 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

Recce Pharmaceuticals Ltd Doses All Patients in Phase II Trial of Recce®? 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

New major risk - Share price stability

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 08, 2023

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

New minor risk - Financial data availability

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

New major risk - Share price stability

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

CEO, MD & Executive Director recently bought €190k worth of stock

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Less than half of directors are independent

Less than half of directors are independent

Chinese Patent Office Grants Anti-Viral Patent to Recce Pharmaceuticals Ltd

Board Member recently sold €113k worth of stock

Recce Pharmaceuticals Ltd. Provides Recce Clinical Pipeline Update

Shareholder Returns

Price Volatility